Drug Database
BU

buprenorphine

✓ Approved

Roche · OPRK1 · 小分子

什么是 buprenorphine?

buprenorphine 是一种小分子,由Roche研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)、Sublingual (SL)/Oral Transmucosal。

药物档案

公司Roche
药物类别小分子
分子靶点OPRK1, OPRM1
给药途径Oral (PO), Sublingual (SL)/Oral Transmucosal
状态Approved

作用机制

分子靶点

buprenorphine 作用于 2 个分子靶点:

OPRK1opioid receptor kappa 1 (KOR1, OPRK)
OPRM1opioid receptor mu 1 (MOR1, LMOR)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

buprenorphine 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Gastrointestinal disordersAbdominal pain✓ Approved

相关研究文献

PubMedHarm reduction journal2026-11-19

Multi-stakeholder perspectives on acceptability and delivery of buprenorphine for women who use drugs.

Austin Elizabeth J EJ, Violette Lauren R LR, Stewart Jenell J, Glick Sara N SN et al.

Women who use drugs (WWUD) face substantial barriers to accessing medications for opioid use disorder (MOUD), including buprenorphine. As part of a formative evaluation to co-design a community-based intervention for MOUD delivery, we explored multi-stakeholder perspectives on the acceptability and delivery of buprenorphine for WWUD. We conducted qualitative interviews with 16 WWUD (who reported lifetime history of injection drug use) and 5 healthcare and harm reduction professionals (HHRP) who work closely with WWUD. Interviews asked open-ended questions about attitudes and beliefs towards buprenorphine, experience receiving (WWUD) or facilitating receipt (HHRP) of buprenorphine, and barriers to using buprenorphine in the future. Interviews were audio-recorded, professionally-transcribed, and coded using Rapid Assessment Process. Two coders generated templated coding summaries of each transcript, which were placed into a matrix and iteratively reviewed to identify cross-cutting themes. Qualitative learnings were finalized with the investigative team and confirmed with community advisors. Among 16 WWUD participants, 12 (75%) identified as White and 11 (69%) were unstably housed. All participants had a lifetime history of injection drug use and 10 (63%) had ever tried buprenorphine. Most WWUD did not perceive buprenorphine to be the right choice for them, in part due to beliefs about its limited effectiveness and concerns about their personal safety and stigmatizing beliefs. Fear of physical discomfort from buprenorphine inductions further discouraged willingness, especially for those using fentanyl. Participants described the ways in which housing instability and limited social supports compounded barriers to starting and staying on buprenorphine, but that harm reduction approaches might help. WWUD face multilevel barriers to buprenorphine use and both WWUD and HHRP are working to respond to the ways in which fentanyl further heightens those barriers. Future efforts to expand buprenorphine use among WWUD should consider supports that improve the ease and acceptability of buprenorphine delivery.

PMID 43053082
阅读全文 →
PubMedBMC medical imaging2026-11-19

Body size-normalized quantitative assessment of coronary lumen volume following sublingual nitroglycerin at CT angiography.

Balaban Ismail I, Alicioglu Banu B

Sublingual nitroglycerin is widely used before coronary computed tomography angiography to induce coronary vasodilation and enhance visualization of distal coronary segments and small side branches. The aim of the study was to assess the effect of sublingual nitroglycerin on whole-vessel coronary lumen volume in coronary computed tomography angiography and to determine whether this response varies after normalization for body size parameters. This single-center retrospective comparative study included patients who underwent coronary computed tomography angiography using a 128-detector computed tomography scanner. Patients were classified according to pre-scan nitroglycerin administration. In the nitroglycerin group, 400 µg of sublingual nitroglycerin was administered 3-5 minutes before image acquisition. Age-matched patients who did not receive nitroglycerin served as controls. Coronary lumen volumes were calculated semi-automatically using dedicated software and normalized to body mass index and body surface area. The number of coronary side branches and intraluminal contrast enhancement in proximal and distal segments were also assessed. A total of 194 patients were included. Compared with controls, the nitroglycerin group demonstrated significantly larger median coronary lumen volumes (left anterior descending artery: 519 vs 429 mm3, right coronary artery: 634 vs 468 mm3, left circumflex artery: 381 vs 249 mm3), together with higher body size-normalized lumen volumes (all p ≤ 0.009). The number of septal, diagonal, and obtuse marginal branches was also significantly higher in the nitroglycerin group (p < 0.001). The proximal-to-distal contrast enhancement ratios of the left anterior descending and left circumflex arteries were significantly lower in the nitroglycerin group (p < 0.001). Sublingual nitroglycerin significantly increases whole-vessel coronary lumen volume on coronary computed tomography angiography. This quantitative volumetric effect persists after body size normalization and may improve coronary visualization in patients with larger body habitus.

PMID 43052801
阅读全文 →
PubMedJournal of pain and symptom management2026-11-18

Divergent Mechanisms of Reward Reduction in Buprenorphine and Methadone: Implications for Opioid Selection in Cancer Pain with Elevated Misuse Liability.

Davis Mellar P MP

Buprenorphine and methadone both reduce opioid reward, but by distinct mechanisms: buprenorphine competitively blunts a co-administered full agonist's reward, whereas methadone's reduced reward is a receptor-selective property of methadone itself, not a blocking action transferable to a second agonist.

PMID 43051325
阅读全文 →
PubMedDrug and alcohol dependence2026-11-18

Higher county-level need is associated with greater naloxone distribution from U.S. syringe services programs in 2023: A cross-sectional study.

Lambdin Barrot H BH, Humphrey Jamie J, Saunders McKinley M, Wenger Lynn L et al.

To assess whether U.S. syringe services programs (SSPs) in counties with higher levels of need in 2022 had greater financial resources and larger-scale delivery of overdose prevention interventions in 2023. This study utilized a cross-sectional design. As a measure of underlying, community-level need, our primary exposure was 2022 county-level opioid overdose fatalities, categorized as low (1-33), moderate (34-198), or high (199-1923). Outcomes included annual SSP budget, number of naloxone recipients from the SSP, naloxone doses distributed by the SSP, and buprenorphine availability at the SSP. Using weighted generalized estimating equations with exchangeable correlation structures to account for clustering of SSPs within Census divisions, we used gamma, negative binomial, and logit specifications as appropriate for each outcome. SSPs reported a median budget of $141,842; 596 naloxone recipients; 2001 naloxone doses distributed; and 44% had integrated buprenorphine. Compared to SSPs in low overdose fatality counties, SSPs in moderate- and high overdose fatality counties had significantly larger budgets, greater number of naloxone recipients and greater number of naloxone doses distributed. SSPs in higher need counties were not significantly more likely to have buprenorphine available (aOR=1.40; 95% CI:0.72-2.75; p = 0.321). Our findings showed that higher levels of need were positively associated with greater financial resources for and naloxone distribution from SSPs in 2023 but was not associated with greater buprenorphine availability. Aligning higher levels of naloxone distribution with higher need maximizes potential for population health impact. Focused infrastructure and implementation support for buprenorphine integration at SSPs likely remain.

PMID 43050840
阅读全文 →
PubMedPsychopharmacology2026-11-18

Psychedelic experience intensity during ketamine treatment and antidepressant outcomes.

Mathai David S DS, Goldy Sean P SP, Hull Thomas D TD, Arden Kristin K et al.

Ketamine is an effective antidepressant, but the role of acute subjective effects in treatment response remains unclear. Prior studies rely largely on dissociation measures focused on adverse events, which may not capture broader effects across multiple phenomenological domains. To evaluate whether subjective psychedelic intensity during ketamine treatment, considered beyond an adverse-event framework, is associated with antidepressant outcomes. In this retrospective longitudinal cohort study, 3,637 adults with moderate-to-severe depression received up to 4 doses of sublingual ketamine over 4 weeks within a telehealth-supported treatment program. Subjective effects were assessed using the Mindbloom Psychedelic Intensity (MPI) scale, a novel 5-item measure capturing emotional, cognitive, physical, visual, and auditory effects. Primary outcomes included end-of-treatment change in Patient Health Questionnaire-9 (PHQ-9) scores, clinically significant change, and treatment response trajectories. Pre-registered analyses evaluated whether MPI scores at the midpoint of treatment were associated with antidepressant outcomes. Higher subjective intensity scores at 2 weeks were associated with greater reductions in depression severity at 4 weeks, increased likelihood of clinically significant change, and greater likelihood of membership in an improvement trajectory, independent of dose and other covariates. Subjective intensity of the ketamine experience was robustly associated with antidepressant outcomes. These findings suggest that subjective drug effects represent a clinically meaningful correlate of treatment response and highlight the importance of assessments designed to capture first-person experiences with ketamine, with implications for future mechanistic research and clinical care.

PMID 43045823
阅读全文 →
PubMedActa biomaterialia2026-11-17

Mucoadhesive carboxymethyl cellulose-pullulan dissolving microneedles for sublingual delivery of peanut allergens in immunotherapy.

Kim Minsoo M, Nam Jeehye J, Park Shinyoung S, Cho Sung Min SM et al.

Peanut allergy remains a major clinical challenge due to the risk of severe anaphylaxis and limitations associated with current immunotherapies, including poor compliance in oral immunotherapy (OIT) and insufficient antigen retention in sublingual immunotherapy (SLIT). In this study, we developed a polysaccharide-based sublingual dissolving microneedle immunotherapy (SDMNIT) platform composed of a mucoadhesive carboxymethyl cellulose-pullulan (CMC-PL) film optimized for sublingual retention, a CMC-PL-hyaluronic acid (HA) base matrix engineered to suppress salivary leakage and improve localized payload confinement, and peanut extract (PE)-loaded HA microneedle tips for efficient allergen deposition into the sublingual mucosa. In vitro characterization demonstrated favorable rheological behavior, controlled dissolution, enhanced mucoadhesion, reduced salivary washout, and efficient sublingual insertion with localized payload retention under simulated oral conditions. In vivo evaluation in peanut-sensitized mice showed that SDMNIT attenuated challenge-induced allergic responses and was associated with reduced histamine and PE-specific immunoglobulin E (IgE) levels and changes in antibody and splenic cytokine profiles. Allergen-specific measurements also demonstrate tissue-associated Ara h 2 after sublingual administration. Overall, these findings support that SDMNIT enables effective localized mucosal immune modulation and dose-sparing allergen delivery under dynamic sublingual conditions, thereby providing a promising platform for the development of advanced allergen-specific immunotherapy approaches for peanut allergy. STATEMENT OF SIGNIFICANCE: Current allergen immunotherapies, including oral immunotherapy (OIT) and sublingual immunotherapy (SLIT), are limited by gastrointestinal (GI) exposure, poor allergen retention, and imprecise mucosal delivery, reducing therapeutic efficacy and patient compliance. This study presents a rationally engineered carbohydrate polymer-based sublingual dissolving microneedle immunotherapy (SDMNIT) platform that integrates complementary biomaterial functions through a mucoadhesive carboxymethyl cellulose (CMC)-pullulan (PL) film, a CMC-PL-hyaluronic acid (HA) base, and peanut extract (PE)-loaded HA microneedles (MNs). Systematic optimization of the multilayer structure improved localized allergen delivery, enhanced immune modulation, and enabled dose-sparing therapeutic efficacy in peanut-sensitized mice. This work demonstrates how biomaterial engineering can improve allergen-specific mucosal immunotherapy and provides a broadly applicable strategy for localized transmucosal drug delivery.

PMID 43044703
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多buprenorphine